| Market Cap | 76.16M | P/E | - | EPS this Y | 9.60% | Ern Qtrly Grth | - |
| Income | -29.1M | Forward P/E | -3.00 | EPS next Y | 33.30% | 50D Avg Chg | -33.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -40.00% |
| Dividend | N/A | Price/Book | 3.33 | EPS next 5Y | - | 52W High Chg | -72.00% |
| Recommedations | 2.00 | Quick Ratio | 0.08 | Shares Outstanding | 61.49M | 52W Low Chg | 6.00% |
| Insider Own | 2.92% | ROA | -61.41% | Shares Float | 59.70M | Beta | 0.66 |
| Inst Own | 10.31% | ROE | -250.20% | Shares Shorted/Prior | 4.42M/4.70M | Price | 1.53 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 277,291 | Target Price | 7.73 |
| Oper. Margin | - | Earnings Date | Dec 19 | Volume | 526,513 | Change | -6.13% |
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
| EF Hutton | Buy | Jul 12, 23 |
| EF Hutton | Buy | Mar 9, 23 |
| EF Hutton | Buy | Dec 29, 22 |
| EF Hutton | Buy | Apr 7, 22 |
| HC Wainwright & Co. | Buy | Jan 13, 20 |
| Taglich Brothers | Speculative Buy | Feb 20, 13 |
| Chardan Capital | Buy | Feb 13, 13 |
| Laidlaw & Co. | Buy | Jan 14, 13 |